Prospective evaluation of cardio-metabolic comorbidities in a cohort of patients with non-cystic fibrosis bronchiectasis
Abstract
Results In total, 336 of 457 patients with MINOCA underwent CMR. CMR was able to identify a diagnosis in 90.5% of cases, and changed the underlying cause in 35.7% of patients; 33.7% of type 1 MI were not diagnosed prior to CMR. Patients with a normal CMR had a significantly longer median time to complete the CMR (17 vs. 7 days, P = 4.2E-7) and lower conventional and high sensitivity troponin values (respectively 1.1 vs. 3.6 G/L, P = 0.002 and 433.3 vs. 707.1 ng/L, P = 0.007). At 1-year follow-up of the CMR cohort, the prevalence of all-cause mortality was 3%, of cardiac mortality 0.6% and of rehospitalisation for cardiac causes 7.8%. No bleeding disorders occurred after increased anti-platelet therapy in patients re-diagnosed with MI (Fig. 1). Conclusion CMR provided a diagnosis in 9 out of 10 patients presenting with MINOCA. The diagnosis differed from the one prior to CMR in 35.7% of patients. The systematic use of CMR plays a pivotal role in identifying the underlying cause of myocardial injury, impacting both individuals, health professionals and society at large.